Can Ebola Virus Vaccines Have Universal Immune Correlates of protection?

Meyer, Michelle; Malherbe, Delphine C.; Bukreyev, Alexander

doi:10.1016/j.tim.2018.08.008

“…Recently, some authors have suggested that different CoP might have to be utilized for different EBOV vaccines [36] depending, among other parameters, on the antigen used and the route of vaccination. Thus, we need to apply caution when using solely antibody titration to assess the effectiveness of putative vaccines, as this alone may not reflect immunity.…”

Section: Discussionmentioning

confidence: 99%

Ebola Virus Disease Survivors Show More Efficient Antibody Immunity than Vaccinees Despite Similar Levels of Circulating Immunoglobulins

Koch

¹

,

Rottstegge

²

,

Ruibal

³

et al. 2020

Viruses

View full text Add to dashboard Cite

The last seven years have seen the greatest surge of Ebola virus disease (EVD) cases in equatorial Africa, including the 2013–2016 epidemic in West Africa and the recent epidemics in the Democratic Republic of Congo (DRC). The vaccine clinical trials that took place in West Africa and the DRC, as well as follow-up studies in collaboration with EVD survivor communities, have for the first time allowed researchers to compare immune memory induced by natural infection and vaccination. These comparisons may be relevant to evaluate the putative effectiveness of vaccines and candidate medical countermeasures such as convalescent plasma transfer. In this study, we compared the long-term functionality of anti-EBOV glycoprotein (GP) antibodies from EVD survivors with that from volunteers who received the recombinant vesicular stomatitis virus vectored vaccine (rVSV-ZEBOV) during the Phase I clinical trial in Hamburg. Our study highlights important differences between EBOV vaccination and natural infection and provides a framework for comparison with other vaccine candidates.

show abstract

“…The Ebola crisis calls for a sense of urgency towards the TB epidemic, and for a narrowed focus. For example, the lack of knowledge of correlates of protection has not prevented the advancement of a new malaria, polio [46], or Ebola vaccine [47,48], neither the eradication of small pox [49]. Funds can be prioritized for pre-clinical development and field testing of candidates in order to stop the scourge, else the goal of TB elimination will remain elusive [1].…”

Section: Discussionmentioning

confidence: 99%

Development of a TB vaccine trial site in Africa and lessons from the Ebola experience

Kaguthi

¹

,

Nduba

²

,

Rabuogi

³

et al. 2020

View full text Add to dashboard Cite

Tuberculosis is the deadliest infection of our time. In contrast, about 11,000 people died of Ebola between 2014 and 2016. Despite this manifest difference in mortality, there is now a vaccine licensed in the United States and by the European Medicines Agency, with up to 100% efficacy against Ebola. The developments that led to the trialing of the Ebola vaccine were historic and unprecedented. The single licensed TB vaccine (BCG) has limited efficacy. There is a dire need for a more efficacious TB vaccine. To deploy such vaccines, trials are needed in sites that combine high disease incidence and research infrastructure. We describe our twelve-year experience building a TB vaccine trial site in contrast to the process in the recent Ebola outbreak. There are additional differences. Relative to the Ebola pipeline, TB vaccines have fewer trials and a paucity of government and industry led trials. While pathogens have varying levels of difficulty in the development of new vaccine candidates, there yet appears to be greater interest in funding and coordinating Ebola interventions. TB is a global threat that requires similar concerted effort for elimination.

show abstract

“…The Ebola crisis calls for a sense of urgency towards the TB epidemic, and for a narrowed focus. For example, the lack of knowledge of correlates of protection has not prevented the advancement of a new malaria, polio (46), or Ebola vaccine (47,48), neither the eradication of small pox (49). Funds can be prioritized for pre-clinical development and eld testing of candidates in order to stop the scourge, else the goal of TB elimination will remain elusive (1).…”

Section: Discussionmentioning

confidence: 99%

Development of a TB vaccine trial site in Africa and lessons from the Ebola experience.

Kaguthi

¹

,

Nduba

²

,

Rabuogi

³

et al. 2020

Preprint

0

View full text Add to dashboard Cite

Tuberculosis is the deadliest infection of our time. In contrast, about 11,000 people died of Ebola between 2014 and 2016. Despite this manifest difference in mortality, there is now a vaccine licensed in the United States and by the European Medicines Agency, with up to 100% efficacy against Ebola. The developments that led to the trialing of the Ebola vaccine were historic and unprecedented. The single licensed TB vaccine (BCG) has limited efficacy. There is a dire need for a more efficacious TB vaccine. To deploy such vaccines, trials are needed in sites that combine high disease incidence and research infrastructure. We describe our twelve-year experience building a TB vaccine trial site in contrast to the process in the recent Ebola outbreak. There are additional differences. Relative to the Ebola pipeline, TB vaccines have fewer trials and a paucity of government and industry led trials. While pathogens have varying levels of difficulty in the development of new vaccine candidates, there yet appears to be greater interest in funding and coordinating Ebola interventions. TB is a global threat that requires similar concerted effort for elimination.

show abstract

Can Ebola Virus Vaccines Have Universal Immune Correlates of protection?

Cited by 33 publications

References 68 publications

Ebola Virus Disease Survivors Show More Efficient Antibody Immunity than Vaccinees Despite Similar Levels of Circulating Immunoglobulins

Ebola Virus Disease Survivors Show More Efficient Antibody Immunity than Vaccinees Despite Similar Levels of Circulating Immunoglobulins

Development of a TB vaccine trial site in Africa and lessons from the Ebola experience

Development of a TB vaccine trial site in Africa and lessons from the Ebola experience.

Contact Info

Product

Resources

About